|
Status |
Public on Feb 12, 2024 |
Title |
Head to head comparison of target knockdown following OTV vs. anti-TfR:ASO administration in mice |
Organism |
Mus musculus |
Experiment type |
Expression profiling by high throughput sequencing
|
Summary |
Using single nucleus RNA sequencing, we determined that peripheral administration of OTV:Malat1 results in much more widespread and robust target knockdown throughout the mouse brain compared to anti-TfR:Malat1.
|
|
|
Overall design |
TfR.KI mice received four weekly doses of 50mpk OTV:Malat1, anti-TfR:Malat1, Malat1 ASO (at an ASO-equivalent dose), or saline. Tissues were harvested 72 hours after the final dose and snap frozen for molecuar analysis.
|
Web link |
https://www.biorxiv.org/content/10.1101/2023.04.25.538145v1
|
|
|
Contributor(s) |
Barker S, Ha C, Tatarakis D, Sandmann T |
Citation missing |
Has this study been published? Please login to update or notify GEO. |
|
Submission date |
Apr 28, 2022 |
Last update date |
Feb 12, 2024 |
Contact name |
David Tatarakis |
E-mail(s) |
tatarakis@dnli.com, genomics@dnli.com
|
Organization name |
Denali Therapeutics
|
Department |
Discovery Genomics
|
Street address |
161 Oyster Point Blvd
|
City |
South San Francisco |
State/province |
California |
ZIP/Postal code |
94080 |
Country |
USA |
|
|
Platforms (1) |
GPL24247 |
Illumina NovaSeq 6000 (Mus musculus) |
|
Samples (17)
|
|
Relations |
BioProject |
PRJNA833038 |